Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 60

1.

New approaches for breast cancer: should Ret kinase be considered as a novel therapeutic target?

Birner P, Bartsch R, Schreiber M, Dubsky P, Kenner L.

Future Oncol. 2014 Feb;10(3):333-6. doi: 10.2217/fon.13.267. No abstract available. Erratum in: Future Oncol. 2014 Mar;10(4):696.

PMID:
24559440
2.

RET in breast cancer: functional and therapeutic implications.

Morandi A, Plaza-Menacho I, Isacke CM.

Trends Mol Med. 2011 Mar;17(3):149-57. doi: 10.1016/j.molmed.2010.12.007. Epub 2011 Jan 19. Review.

PMID:
21251878
3.

RET inhibition: implications in cancer therapy.

Borrello MG, Ardini E, Locati LD, Greco A, Licitra L, Pierotti MA.

Expert Opin Ther Targets. 2013 Apr;17(4):403-19. doi: 10.1517/14728222.2013.758715. Epub 2013 Mar 6. Review.

PMID:
23461584
4.

Current review of small molecule Ret kinase inhibitors.

Zuercher WJ, Turunen BJ, Lackey KE.

Mini Rev Med Chem. 2010 Feb;10(2):138-46. Review.

PMID:
20105131
5.

New approaches to thyroid cancer.

Cohen EE.

Clin Adv Hematol Oncol. 2012 Apr;10(4):255-6. No abstract available.

PMID:
22706487
6.

Targeting RET for thyroid cancer therapy.

Lanzi C, Cassinelli G, Nicolini V, Zunino F.

Biochem Pharmacol. 2009 Feb 1;77(3):297-309. doi: 10.1016/j.bcp.2008.10.033. Epub 2008 Nov 6.

PMID:
19028457
7.

Development of RET kinase inhibitors for targeted cancer therapy.

Mologni L.

Curr Med Chem. 2011;18(2):162-75. Review.

PMID:
21110809
8.

Molecular targeted therapy for neuroendocrine tumors.

Yao JC, Hoff PM.

Hematol Oncol Clin North Am. 2007 Jun;21(3):575-81; x. Review.

PMID:
17548041
9.

Targeting RET receptor tyrosine kinase activation in cancer.

Phay JE, Shah MH.

Clin Cancer Res. 2010 Dec 15;16(24):5936-41. doi: 10.1158/1078-0432.CCR-09-0786. Epub 2010 Oct 7. Review.

10.

Fragment-Based Discovery of a Dual pan-RET/VEGFR2 Kinase Inhibitor Optimized for Single-Agent Polypharmacology.

Frett B, Carlomagno F, Moccia ML, Brescia A, Federico G, De Falco V, Admire B, Chen Z, Qi W, Santoro M, Li HY.

Angew Chem Int Ed Engl. 2015 Jul 20;54(30):8717-21. doi: 10.1002/anie.201501104. Epub 2015 Jun 30.

11.

mTOR inhibitors in advanced breast cancer: ready for prime time?

Martin LA, André F, Campone M, Bachelot T, Jerusalem G.

Cancer Treat Rev. 2013 Nov;39(7):742-52. doi: 10.1016/j.ctrv.2013.02.005. Epub 2013 Apr 1. Review.

PMID:
23557794
12.

New molecular targeted therapies in thyroid cancer.

Milano A, Chiofalo MG, Basile M, Salzano de Luna A, Pezzullo L, Caponigro F.

Anticancer Drugs. 2006 Sep;17(8):869-79. Review.

PMID:
16940797
13.

Identification of two novel RET kinase inhibitors through MCR-based drug discovery: design, synthesis and evaluation.

Frett B, Moccia M, Carlomagno F, Santoro M, Li HY.

Eur J Med Chem. 2014 Oct 30;86:714-23. doi: 10.1016/j.ejmech.2014.09.023. Epub 2014 Sep 8.

14.

The RET proto-oncogene: a potential target for molecular cancer therapy.

Pützer BM, Drosten M.

Trends Mol Med. 2004 Jul;10(7):351-7. Review.

PMID:
15242684
15.

Beyond RET: potential therapeutic approaches for advanced and metastatic medullary thyroid carcinoma.

Santarpia L, Ye L, Gagel RF.

J Intern Med. 2009 Jul;266(1):99-113. doi: 10.1111/j.1365-2796.2009.02112.x. Review.

16.

Inhibitors of the RET tyrosine kinase based on a 2-(alkylsulfanyl)-4-(3-thienyl)nicotinonitrile scaffold.

Brandt W, Mologni L, Preu L, Lemcke T, Gambacorti-Passerini C, Kunick C.

Eur J Med Chem. 2010 Jul;45(7):2919-27. doi: 10.1016/j.ejmech.2010.03.017. Epub 2010 Mar 19.

PMID:
20409618
17.

Discovery of 4-chloro-3-(5-(pyridin-3-yl)-1,2,4-oxadiazole-3-yl)benzamides as novel RET kinase inhibitors.

Han M, Li S, Ai J, Sheng R, Hu Y, Hu Y, Geng M.

Bioorg Med Chem Lett. 2016 Dec 1;26(23):5679-5684. doi: 10.1016/j.bmcl.2016.10.061. Epub 2016 Oct 24.

PMID:
27815117
18.

RET TKI: potential role in thyroid cancers.

Antonelli A, Fallahi P, Ferrari SM, Mancusi C, Colaci M, Santarpia L, Ferri C.

Curr Oncol Rep. 2012 Apr;14(2):97-104. doi: 10.1007/s11912-012-0217-0. Review.

PMID:
22286373
19.

Inhibitors of insulin-like growth factor signaling: a therapeutic approach for breast cancer.

Sachdev D, Yee D.

J Mammary Gland Biol Neoplasia. 2006 Jan;11(1):27-39. Review.

PMID:
16947084
20.

Medullary thyroid cancer: a promising model for targeted therapy.

Torino F, Paragliola RM, Barnabei A, Corsello SM.

Curr Mol Med. 2010 Oct;10(7):608-25. Review.

PMID:
20712590

Supplemental Content

Support Center